Loading
AZD8421 is a small-molecule inhibitor from AstraZeneca, in registered phase 2 trials for ovarian cancer.
AZD8421 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by AstraZeneca, in ovarian cancer. Described in the registry record as a cdk2 inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a cdk2 inhibitor; the trial entries below carry the sponsor's wording.
1.AZD8421 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AZD8421" OR ABSTRACT:"AZD8421") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AZD8421, not a curated reading list.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares AstraZeneca and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares AstraZeneca and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.